Back to News
Market Impact: 0.2
FDA Accepts Curi Bio’s Letter of Intent into ISTAND Program to Qualify 3D Neuromuscular Junction Assay as a Non-Animal Replacement for Botulinum Toxin Potency Testing
Source: Business Wire
Healthcare & BiotechRegulation & LegislationTechnology & InnovationESG & Climate Policy
The FDA accepted Curi Bio into its ISTAND program to pursue qualification of a 3D neuromuscular junction assay as a non-animal alternative for botulinum toxin potency testing. The regulatory engagement could support broader adoption of Curi Bio's assay platform and reduce reliance on animal-based testing, though no financial impact or commercialization timeline was disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
More News
- China's AI leaders keep quiet despite U.S. 'publicity' on tech risks
- Karin Rådström is steering Daimler Truck in a new direction as the world’s biggest truckmaker faces a growing challenge from China
- AWS says it can't restore service to Bahrain, UAE facilities 6 months after Iran strikes
- US Senate crypto bill collapses in blow to industry
- BlackRock’s Fink, Blackstone’s Gray Back Carney’s Canada Investment Push
- Factbox-How AI leaders and world governments react to ’AI doom’ fears